David Clever

TL;DR: An ionic checkpoint that blocks T cell function in tumours is uncovered and potential new strategies for cancer immunotherapy are identified, including boosting potassium efflux in tumour-specific T cells by overexpressing the potassium channel Kv1.3.

TL;DR: Findings identify BACH2 as a key regulator of CD4+ T-cell differentiation that prevents inflammatory disease by controlling the balance between tolerance and immunity.

TL;DR: It is shown that pharmacologic inhibition of Akt enables expansion of TIL with the transcriptional, metabolic, and functional properties characteristic of memory T cells, which results in enhanced persistence of Til after adoptive transfer into an immunodeficient animal model and augments antitumor immunity of CD8 T cells in a mouse model of cell-based immunotherapy.

TL;DR: Use of ΔΨm-based sorting to enrich for cells with superior metabolic features was observed in CD8(+), CD4(+) T cell subsets, and long-term hematopoietic stem cells, and this metabolism-based approach to cell selection may be broadly applicable to therapies involving the transfer of HSC or lymphocytes for the treatment of viral-associated illnesses and cancer.

TL;DR: It is found that the TF BACH2 restrains terminal differentiation to enable generation of long-lived memory cells and protective immunity after viral infection.